WallStSmart

The Ensign Group Inc (ENSG)vsSyra Health Corp. Class A Common Stock (SYRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 69895% more annual revenue ($5.06B vs $7.23M). ENSG leads profitability with a 6.8% profit margin vs -12.4%. ENSG earns a higher WallStSmart Score of 57/100 (C).

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34

SYRA

Avoid

28

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: 0.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSGFair Value (-0.3%)

Margin of Safety

-0.3%

Fair Value

$211.28

Current Price

$203.89

$7.39 premium

UndervaluedFair: $211.28Overvalued

Intrinsic value data unavailable for SYRA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

SYRA2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Areas to Watch

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

SYRA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.11M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-36.0%2/10

ROE of -36.0% — below average capital efficiency

Revenue GrowthGrowth
-13.6%2/10

Revenue declined 13.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bull Case : SYRA

The strongest argument for SYRA centers on Price/Book, Debt/Equity.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Bear Case : SYRA

The primary concerns for SYRA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

ENSG profiles as a growth stock while SYRA is a turnaround play — different risk/reward profiles.

SYRA carries more volatility with a beta of 3.96 — expect wider price swings.

ENSG is growing revenue faster at 20.2% — sustainability is the question.

ENSG generates stronger free cash flow (133M), providing more financial flexibility.

Bottom Line

ENSG scores higher overall (57/100 vs 28/100) and 20.2% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Syra Health Corp. Class A Common Stock

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Syra Health Corp. The company is headquartered in Carmel, Indiana.

Want to dig deeper into these stocks?